PLUS THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
PLUS THERAPEUTICS INC. - More news...
PLUS THERAPEUTICS INC. - More news...
- Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
- Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
- Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
- D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement
- Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
- Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
- Plus Therapeutics Announces New Employment Inducement Grants
- Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
- Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
- Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
- Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
- Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
- Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
- Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
- Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
- Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
- Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
- Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
- Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
- Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
- Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
- Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
- Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
- Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
- Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
- Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
